Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $19.3 million.

  • Compass Therapeutics' Net Cash Flow rose 30.01% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 27.37%. This contributed to the annual value of $19.3 million for FY2024, which is 279.65% up from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Net Cash Flow is $19.3 million, which was up 279.65% from -$10.7 million recorded in FY2023.
  • Over the past 5 years, Compass Therapeutics' Net Cash Flow peaked at $97.2 million during FY2021, and registered a low of -$109.6 million during FY2022.
  • Its 3-year average for Net Cash Flow is -$33.7 million, with a median of -$10.7 million in 2023.
  • In the last 5 years, Compass Therapeutics' Net Cash Flow skyrocketed by 346.31% in 2021 and then crashed by 212.75% in 2022.
  • Over the past 5 years, Compass Therapeutics' Net Cash Flow (Yearly) stood at -$1,121 in 2020, then spiked by 167.60% to $21.8 million in 2020, then skyrocketed by 346.31% to $97.2 million in 2021, then crashed by 212.75% to -$109.6 million in 2022, then skyrocketed by 90.22% to -$10.7 million in 2023, then skyrocketed by 279.65% to $19.3 million in 2024.